ROCO
4107
Market cap237mUSD
Oct 08, Last price
109.50TWD
1D
0.00%
1Q
-6.41%
Jan 2017
-7.98%
IPO
297.46%
Name
Bioteque Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company offers angiography catheter, balloon dilation catheter, guiding sheath, guide steel wire, y-type connector, multi-pipe joint, connecting pipe, y-type connector assembly, peripheral vascular guiding catheter, coronary balloon dilation catheter, central venous catheter, microcatheter assembly, injection tube sleeve assembly for radiographic catheters, micro-puncture guide assembly, closed suction catheter, oxygen masks and tubing, anesthesia mask, sprayer and spray mask, endotracheal tube, and tracheostomy tube. It also provides pig tail drainage tube assembly, pig tail drainage tube, percutaneous drainage catheter accessories, insertion of drainage catheter kit, puncture and insertion system, snap lock drainage catheter set, ureteral catheter, propulsion tube, ureteral balloon dilation catheter, subcutaneous pyelostomy with ureteral catheterization, kidney transplantation ureteral catheter, tumor ureteral catheter, ureteroscopy applicable ureteral catheter, angle sleeve, and urinary tract stone removal products. In addition, it offers blood circuit tube parts, deodorizing and antibacterial spray, biliary balloon dilation catheter, nasobiliary drainage catheter, surgical drainage catheter, leg-binding urine bag, and drainage bag, as well as PVC IV infusion bags, PVC pipe bags, accessories for infusion bags, infusion extension tubing, and IV set. Bioteque Corporation was incorporated in 1991 and is headquartered in Taipei, Taiwan.
Key people
Yu-Jin Lin
Head of Accounting · since 2025
Pei-Zhi Zhong
Corporate Governance Officer · since 2025
Ming-Yeh Cheng
Director · since 2022
Wei-Hsiu Hong
Director · since 2025
Director · since 2024
Yizhong Huang
Chief Financial Officer, Head of Finance, Director · since 2023
Ming-Zhong Li
Chairman of the Board · since 2023
Hong-Ying Li
Director · since 2023
Yi-Xun Li
Senior Deputy General Manager, Director · since 2012
Jin-Long Lin
General Manager, Director · since 2025
Jing-Yi Tsai
Deputy General Manager, Director · since 2025
Xing Wang
Director · since 2022
Yiu-Cho Chin
Independent Director · since 2023
Independent Director · since 2025
Bin-Xi Lin
Independent Director · since 2018
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||